key: cord-1002341-ad758saa
authors: Jena, N. R.
title: Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2
date: 2021-06-30
journal: Chemical Physics Impact
DOI: 10.1016/j.chphi.2021.100011
sha: 6578a0ee1ed5e72069efc27a4ba57589f9d19080
doc_id: 1002341
cord_uid: ad758saa

The recent outbreak of COVID-19 has affected human lives severely. The human-to-human transmission of this viral disease has become deadly due to the unavailability of COVID-19 specific drugs. Here, an overview of various attempts made to design different therapeutic agents against various structural and non-structural proteins of SARS-CoV-2 has been summarized. Emphasis has been made to highlight the mechanisms of drug action and ways to design better inhibitors of these proteins. The roles of anti-oxidants and vitamins in suppressing COVID-19 are also discussed.

The recent outbreak of the coronavirus disease 2019 (COVID-19) has proven to be severely detrimental to the socio-economic conditions of several countries. This pandemic had originated in the city of Wuhan, in China [1] [2] [3] [4] in December 2019 and has now infected about 69 million people and killed about 1.6 million people in almost 200 countries worldwide till December 2020. Although common colds, sneezing, etc. are mediated by coronaviruses, which affect the upper respiratory tracts [5] , COVID-19 is a completely new type of viral disease that mainly affects the lower respiratory tracts [6] . The human-to-human transmission of the COVID-19 has made it a very deadly pandemic. It is believed that the virus can move from the lower respiratory tracts to the gastrointestinal tract, heart, kidney, liver, and central nervous system, leading to the dysfunction of multiple organs [7] . Once the virus enters humans, it grows rapidly. During this period, a high level of immune system proteins called cytokines is produced to protect cells from viral attack. However, high concentrations of pro-inflammatory cytokines, such as interleukin (IL) − 1b, IL-6, and tumor necrosis factor-(TNF-) can affect normal cells and tissues of the patients. This process is called a cytokine storm [8] [9] [10] [11] , which ultimately contributes to acute respiratory distress syndrome (ARDS) [12] . Further, the elevated levels of cytokines in the blood suppress oxygen utilization in the body and leads to the failure of multiple organs [13] and eventually death. It should be mentioned that the cytokines are mainly secreted by innate immune cells such as monocytes, macrophages, etc. that are supposed to act in the early stage of infection. However, cytokine storm occurs at the late stage of SARS-CoV-2 infection, when the adaptive immune response becomes prominent.

The coronavirus that causes COVID-19 was found to be genetically similar to the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused severe respiratory disorders in infected humans in the year 2002 [14] . Due to this reason, the coronavirus 2019 was named SARS-CoV-2 by the World Health Organization (WHO) in February 2020 [15] . Interestingly, SARS-CoV-2 and SARS-CoV were found to belong to the family of -coronaviruses that contain the large Spike proteins on the virus surface that give them a crown-like shape (and hence the name coronavirus). The SARS-CoV-2 was found to contain a single-stranded positive-sense RNA encapsulated within a membrane envelope, which is decorated by several glycoproteins like Spike and Envelop proteins ( Fig. 1 ) [ 16 , 17 ] . While the Spike protein binds to the host protein and is necessary for the entry of the virus into the host cells, the Envelop protein is necessary for the assembly and budding of the virus within the host cells. The viral genome contains a long single-stranded RNA having 26,000 to 32,000 bases and is wrapped by the Nucleocapsid protein to make the nucleocapsid ( Fig 1 ) . The genomic RNA of SARS-CoV-2 contains about six open reading frames (ORFs) [16] [17] [18] [19] . The first ORF (ORF 1a/b) is involved in translating two polypeptides commonly referred to as pp1a and pp1ab to 16 non-structural proteins (nsp1-nsp16) [16] [17] [18] [19] . These non-structural proteins are involved in producing subgenomic RNAs, which code for four main structural proteins, such as Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N) proteins [16] [17] [18] [19] . Consequently, these structural proteins form the mature virions within the endoplasmic reticulum-Golgi intermediate compartment. It should be mentioned that about 29 proteins were found to be formed from the viral RNA that includes 4 structural proteins and 25 non-structural and accessory proteins ( Fig. 1 ) [16] [17] [18] [19] . The non-structural proteins (nsp) are expressed as two huge polyproteins that are cleaved into 16 smaller proteins by the viral proteases [16] . Several of these proteins are not yet fully characterized. However, it is believed that nsp1 and nsp3 are responsible for the inhibition of IFN signaling and blocking of host innate The structure of the viral particle that contains the RNA genome wrapped up by different structural proteins and the translation of viral RNA to structural and non-structural proteins. Other than these, several accessory proteins are also produced from the viral RNA after entering into the host cells.

immune response by the promotion of cellular degradation and blocking of host RNA translation [20] . The nsp2 acts by decreasing interferon (IFN) production and suppressing antiviral responses. The nsp3 (papainlike protease or PL pro ) and nsp5 (cysteine-like main protease or M pro or CL pro ) promote cytokine expression and help in the photolytic cleavage of viral polyprotein. Similarly, nsp4 and nsp6 contribute to the structure of transmembrane scaffold protein (double-membrane vesicle formation), while the complexation of nsp7 and nsp8 helps in the processing of viral RNA by nsp12 (RNA-dependent RNA polymerase) [20] . The nsp9 plays the role of RNA binding protein phosphatase, while nsp10, nsp16, and nsp14 stimulate ExoN and 2-O-MT activity [20] . The nsp12 is the RNA-dependent RNA-polymerase, which helps in the RNA synthesis. The nsp13 is an RNA helicase and possesses nucleoside triphosphatase (NTPase) activities [20] . Similarly, nsp14 helps in the proofreading of the viral genome and nsp15 plays the role of viral endoribonuclease and chymotrypsin-like protease activities. The nsp16 is responsible for silencing melanoma differentiation-associated protein 5 (MDA5) and the inhibition of innate immunity regulation [20] .

The virus S-protein is mainly responsible for the intrusion of the virus into the host cells by interacting with the angiotensin-converting enzyme 2 (ACE2) located on the human respiratory cell membrane mainly found in lungs [21] . Before and after the binding of the S-protein to the ACE2 receptor, it undergoes various conformational changes to adapt a postfusion conformation [22] [23] [24] [25] . As a result, the repulsive force between the lipid bilayers of the virus and host cells decreases, which ulti-mately helps in the fusion of the virus into the host cells [25] . Soon after this fusion, the viral genome is released as a single-strand RNA, which gets replicated by the RdRp protein to produce more viral genomes ( Fig. 1 ). Subsequently, these genomes are translated to viral polyproteins by using the human translation machinery, which is then cleaved to produce smaller functional proteins by two viral proteases, such as the main protease (M pro or 3CL pro ) and papain-like protease (PL pro ) ( Fig. 1 ). As the virus keeps multiplying, it reaches the lungs, causing inflammation and pneumonia [ 1 , 2 ] . The inflamed lungs make it difficult for the person to breathe leading to acute respiratory distress syndrome (ARDS) between day eight and day 15 of the onset of symptoms [26] .

Given the profound effects of SARS-CoV-2 on human health and life, it is necessary to design drugs that can stop the intrusion and proliferation of the virus inside the host cells. As the SARS-CoV-2 virus affects host cells in many ways, a combination of drugs or a drug having multiple targets would be required that may inhibit both the intrusion and proliferation of the virus. For example, combining the use of a therapeutic candidate to disrupt the interactions between the S-protein and ACE2 receptor and another drug to inhibit the replicative or translation machinery of the virus would yield better results against COVID-19. Similarly, as different proteins such as RdRp, nsp7, nsp8, nsp13, etc. contribute to the replication of the virus, one drug targeting one replicative protein may not yield the desired result. Moreover, in the case of drug resistance, if one drug loses its activity, other drugs may still work to suppress the replication of the virus. For example, in the [25] . Out of three protomers, only one protomer is shown for clarity. (a) The S-protein is in the prefusion conformation. (b) The binding of RBD to ACE2 (PDB ID 6LZG) [31] . (c) The postfusion conformation of the S2 subunit of the S-protein after its dissociation from the S1 subunit (PDB ID 6XRA). (d) The amino acid residues involved in forming various regions of the complete S-protein are indicated. The important domains, such as the N-terminal domain (NTD), receptor-binding domain (RBD), C-terminal domain 1 (CTD1), C-terminal domain 2 (CTD2), fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), central helix region (CH), and connector domain (CD) are shown in different colors. The S1 and S2 cleavage site (S1/S2) and the S2 ′ cleavage site (S2 ′ ) are also shown. case of HCV virus, the uses of multiple drugs, targeting multiple targets, such as (a) Elbasvir and Grazoprevir for the inhibitions of nsp5A and nsp3/4A protease respectively [27] , (b) Sofosbuvir and Velpatasvir for the inhibitions of nsp5B and nsp5A respectively [28] , and (c) Glecaprevir and Pibrentasvir for the inhibitions of nsp3/4A and nsp5A respectively [29] were shown to yield better results compared to a single drug. However, these drugs should be specific to their targets and avoid binding to off-targets to induce side effects. Also, these drugs should be very stable (not degradable) to avoid inducing toxicities. Hence, it is important to understand the roles of both structural and non-structural proteins of SARS-CoV-2 and the mechanisms of suppression of their activities by novel therapeutics. In this piece of article, a summary of recent attempts made to identify different drugs targeting these proteins are discussed in detail.

As the binding of the S-protein of SARS-CoV-2 to the ACE2 receptor is necessary for the entry of the virus into the host cells, it is necessary to design therapeutic candidates to inhibit the binding of these proteins. To do so, it is important to understand the structural details of the S-protein and the ACE2 receptor in detail. Recent structural studies have revealed that the S-protein is a trimer and possesses two subunits (S1 and S2). The S1 subunit is located within the N-terminal (Residues 14-685) region of the S-protein, which includes the receptor-binding domain (RBD), and receptor binding motif (RBM) [ 25 , 28-32 ] . The S2 subunit contains fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), transmembrane domain (TM), and a cytoplasmic domain (CP) [ 25 , 30 , 34 ] ( Fig. 2 ) . Initially, the S-protein exists in the metastable prefusion conformation and undergoes appreciable structural reorientations before binding to the ACE2 receptor [22] . In a cryo-EM study by considering only the RBD of the S-protein, it was found that the ACE2 makes about 5 hydrogen bonds with the RBD [31] . The binding affinity of the ACE2-RBD complex of SARS-CoV-2 was measured to be 15 nM, which was estimated to be about 10-20 fold higher than that of SARS-CoV [31] . This high binding affinity was proposed to be responsible for rapid human-to-human transmission of the SARS-CoV-2 infection. In another Cryo-EM study involving an entire S-protein structure, it was found that the RBD of S-protein is recognized by the extracellular peptidase domain of ACE2 mainly via polar residues [33] . However, in a subsequent crystallographic study, 13 hydrogen bonds and two salt bridge interactions between ACE2 and the RBM of SARS-CoV-2 were observed [34] . The same number of interactions were also found between ACE2 and SARS-CoV. It was further revealed that the dissociation constant of ACE2 and SARS-CoV-2 ( k d = 4.7 nM) is similar to that of ACE2 and SARS-CoV ( k d = 31 nM) and hence it was proposed that the binding affinity of both the viral proteins would be the same [34] . Due to this reason, the superior binding of S-protein to ACE2 was discarded as the main reason for the better cell fusion of SARS-CoV-2.

Subsequent studies have found a unique RRAR Furin cleavage site at the boundary between the S1 and S2 subunits of SARS-CoV-2, which facilitates the cleavage of the S-protein into the S1 and S2 subunits by the Furin protease [23] . This cleavage was envisioned to be one of the vital causes of the better cell fusion of the SARS-CoV-2 compared to SARS-CoV [34] . Interestingly, recently, neuropilin-1 (NRP1), which is abundantly expressed in the respiratory and olfactory epithelium, has been shown to bind to the Furin-cleaved S1 fragment of the S-protein. This binding is also proposed to elevate the viral infection in humans [35] . Similarly, the priming of the S2 subunit by the transmembrane protease serine 2 (TMPRSS2) after its dissociation from the S1 subunit was also envisioned to be another reason for the superior cell invasion ability of the SARS-CoV-2 [24] . It was also proposed that the priming of the S2 subunit leads to its reversible folding into a postfusion conformation in which the heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains bind to each other strongly [25] . All these factors must be collectively responsible for the rapid human-to-human transmission of the SARS-CoV-2. Therefore, the blocking of the ACE2 binding site, Furin protease, TMPRSS2 protease, NRP1, and interfaces of HR1 and HR2 domains are important to suppress the interactions between the virus and host cells.

Although SARS-CoV-2 specific drugs have not yet been developed, several drugs meant for the treatment of other viral diseases have been suggested to be useful for the treatment of COVID-19. Among these drugs, Arbidol (umifenovir), which is known for its ability to inhibit the fusion of the influenza virus with the host cell, has been proposed to be useful for COVID-19 [ 36 , 37 ] . In a recent study, Arbidol was administered to the patients in three stages of SARS-CoV-2 infection, such as the entry-stage, the post-entry stage, and the entire process of infection. It was found that it blocked both entry (about 75% inhibition) and postentry stages (about 55% inhibition) of the virus efficiently [36] . As the entry-stage shows more inhibitory activity, Arbidol was presumed to act either by targeting the S-protein or ACE2 [36] . Molecular dynamics simulations have shown that Arbidol binds to the S-protein and obstructs its trimerization [37] . In the case of the influenza virus, Arbidol was found to bind to the hydrophobic pocket of the fusion subunit of the viral protein and impeds the low-pH conformational changes of the protein [38] .

In the hepatitis C virus, it was observed to hinder both virus attachment and intracellular vesicle trafficking [39] . These studies indicate that Arbidol is an effective drug against the fusion of the virus into the host cells.

Chloroquine, a malaria drug, has been shown to decrease the viral load in patients infected by SARS-CoV-2 [40] . Derivatives of Chloroquine, such as Hydroxychloroquine and Hydroxychloroquine sulfate were also shown to have better effects on SARS-CoV-2 infected patients [41] [42] [43] . It is believed that these malaria drugs may act on SARS-CoV-2 in multiple ways ranging from impairing glycosylation of ACE2, thereby preventing its binding to the S-protein and inhibiting the replication, assembly, and release of the virus. It was also proposed that Chloroquine can increase the pH of acidic vesicles, such as endosomes and lysosomes, thereby preventing uncoating of the viral envelope and releasing of the RNA into the host cell cytoplasm [41] . In a recent clinical trial study, Hydroxychloroquine alone and in combination with the antibiotic drug Azithromycin was given to COVID-19 patients [42] . It was found that about 100% of patients treated with Hydroxychloroquine in combination with Azithromycin were cured, while about 57.1% of patients treated with Hydroxychloroquine alone were cured [42] . However, in certain studies, Hydroxychloroquine was shown to be ineffective against COVID-19 [44] .

Recently, Nafamostat [45] and its derivative Nafamostat mesylate were found to suppress the S-protein-initiated fusion in 293FT cells (derived from the human fetal kidney) presumably by inhibiting TMPRSS2. Similarly, Camostat mesylate [45] is in a clinical trial for its ability to inhibit TMPRSS2 and prevent virus fusion. However, the inhibiting potential of Nafamostat mesylate was proposed to be 15-fold higher than that of Camostat mesylate [45] . Although several inhibitors of Furine protease have been proposed [46] , the one which can benefit COVID-19 patients is scarce.

In addition to small molecule inhibitors, peptide-inhibitors can also play a vital role in the inhibition of S-protein. For example, recently several lipopeptides derived from EK1 were shown to inhibit the S-proteinmediated membrane fusion and pseudovirus infection by binding to the HR1 domain of the S2 subunit [47] . Among these peptides, the EK1C4 was found to be the most effective. In another study, peptides derived from the HR1 and HR2 conserved regions of S-proteins across different coronaviruses (SARS-CoV and MERS-CoV) were also shown to inhibit the fusion of S-protein of SARS-CoV-2 by blocking the interactions between HR1 and HR2 domains [48] . Due to the same reason, a lipopeptide inhibitor (IPB02) derived from the sequence of the HR2 domain was shown to inhibit the S-protein-mediated cell-cell fusion and pseudovirus transduction [49] .

It is now established that M pro (or CL pro ) and PL pro are responsible for the cleavage of pp1a and pp1ab to several non-structural proteins [50] [51] [52] [53] . The M pro is mainly responsible for the cleavage of nsp4-nsp16, while PL pro is responsible for the cleavage of nsp1-nsp3 [50] . Hence, these proteases play an important role in the replication and translation of SARS-CoV-2 [51] . Therefore, their inhibitions can suppress both replication and translation of the SARS-CoV-2.

Structural studies have revealed that the M pro is a three-domain (domain I (residues 8-101), domain II (residues 102-184), and domain III (residues 201-303)) containing cysteine protease [ 52 , 53 ] . The substrates of M pro contain an amino acid sequence -P4-P3-P2-P1 ↓P1 ′ -P2 ′ -P3 ′ -, with the cleavage site between P1 and P1 ′ (represented by ↓) [ 52 , 43 ] . It was found that Gln is almost always present at the P1 position and plays an important role in substrate recognition. It was further found that the active site of M pro lies between domains I and II, which contains a characteristic Cys-His (Cys145-His41) dyad that plays a prominent role in substrate catalysis [ 52 , 53 ] . It also contains four vital sites namely S1 ′ , S1, S2, and S4 as illustrated in Fig.3 . In the M pro structure of SARS-CoV-2, the Cys145, Gly143, and Ser144 were found to be located at the S1 ′ , His163 was located at the S1 site, and Glu166 and Gln189 were located at the S2 site [52] . Similarly, the Gln189 and Pro168 were located at the S4 site. It was proposed that inhibitors of M pro would make a covalent linkage with the thiol group of Cys145 located in the S1 ′ site and make interactions with residues of S1-S4 sites. Based on these findings, two new inhibitors, such as 11a and 11b were recently shown to inhibit the activities of M pro protease of SARS-CoV-2 [52] . As 11a was found to possess low toxicity, it was proposed to be the better inhibitor. For the same reasons, an -ketomide-inhibitor (13b) has been shown to inhibit M pro [53] . The pharmacokinetic characterization of this inhibitor was found to show a pronounced lung tropism and suitable for intake by inhalation [53] .

Lopinavir is an HIV protease inhibitor, which is used in combination with other protease inhibitors like Ritonavir for the treatment of AIDS [54] . Although Ritonavir was discovered as an HIV protease inhibitor [55] , it is advantageous when used with other HIV protease inhibitors, presumably due to its ability to inhibit cytochrome P450-3A4 that normally metabolizes different protease inhibitors [56] . It was shown that the combination of Lopinavir and Ritonavir can decrease the virus load in COVID-19 patients [57] . It should be mentioned that in this study [57] a combination of these drugs was given to 47 patients (22 male and 25 female) suffering from COVID-19. These patients were categorized into two groups, namely the test group ( n = 42) and the control group ( n = 5). The control group was treated with adjuvant drugs (interferon aerosol inhalation, arbidol tablets, eucalyptol limonene, and pinene enteric soft capsules, etc.) and the test group was treated with the Lopinavir and Ritonavir combination along with the adjuvant drugs. It was found that both groups achieved a good therapeutic effect with the body temperature of patients decreased gradually from the date of admission to the 10th day of treatment. However, the body temperature of patients in the test group decreased faster than that in the control group. Further, the abnormal proportion of white blood cells, lymphocytes, and C-reactive protein of the test group were found to be significantly reduced compared to the control group. It was thus found that the number of days required to turn the reverse-transcriptase-polymerasechain-reaction (RT-PCR) positive to negative were significantly reduced in the test group than that in the control group [57] . However, in a subsequent study, based on IC 90 values (drug concentration required to inhibit 90% of the replication of SARS-CoV-2), Lopinavir was found to be ineffective for the treatment of COVID-19 patients [58] . In another study, a total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization, in which 94 patients were treated with the Lopinavir-Ritonavir combination and others were assigned the standard-care treatment [59] . Although the number of patients suffering from ARDS, acute kidney injury, heart failure, etc. were lower in the Lopinavir-Ritonavir group compared to the standard group, other adverse effects, such as vomiting, nausea, etc. were observed in the Lopinavir-Ritonavir group. Based on these results, it was concluded that the Lopinavir-Ritonavir combination has no significant effect on COVID-19 patients [59] . Molecular docking and 10 ns MD-simulation studies have shown that a combination of Lopinavir and Ritonavir can bind to the active site of M pro of SARS-CoV-2 tightly [60] . However, as normally it takes a millisecond time scale to understand the actual function of a protein, 10 ns MD-simulation is too short to understand the binding modes of these drugs [60] . Hence, more research on these drugs is required to establish their effects on the inhibition of protease activities of SARS-CoV-2.

Danoprevir, which is an HCV NS3 protease inhibitor [61] , was also proposed to be advantageous against COVID-19 when consumed in combination with Cobicistat [62] or Ritonavir (for boosting drug metabolism by inhibiting the cytochrome P450 (CYP3A)). It was recently shown that the binding site of HCV NS3 protease inhibitor is structurally similar to that of M pro of SARS-CoV-2 and hence inhibitors of HCV NS3 protease like Danoprevir can also bind to the active site of M pro [61] [62] [63] . Due to this reason, ASC-09 (TMC-310911) has been suggested to be useful against COVID-19 when taken in combination with other antiviral drugs like Ritonavir [64] .

A recent virtual screening study on 2100 compounds from the CHEMBL database, ZINC database, and FDA-approved drugs and molecules under clinical trials followed by subsequent MD-simulation studies have shown that Cobicistat, Ritonavir, Lopinavir, and Darunavir would act as potent inhibitors of M pro [65] . Virtual screening and MDstudies have also identified other FDA-approved drugs [66] [67] [68] for the inhibition of M pro . However, in vivo studies of these ligands can only yield their true efficacy against M pro . Similarly, several covalent inhibitors, such as ketone-based covalent inhibitors [69] , cysteine focussed covalent inhibitors [70] , etc. were proposed for the inhibition of M pro . These inhibitors were proposed to chemically modify the Cys-His dyad, thereby suppressing their ability to influence substrate binding and catalysis. Although covalent inhibitors that can make a covalent bond with the target nucleophilic amino acid (like cysteine, serine, threonine, tyrosine, or lysine) of a protein via its reactive functional group like hydroxyl, or epoxy, or carbonyl, etc., thereby inhibiting the catalysis of the substrates, these inhibitors are less attractive due to their toxicities owned by the fragments formed during the chemical reaction [71] . Hence, in vivo evaluations of both potency and toxicities of such inhibitors are required before using them against COVID-19.

Dipyridamole (DIP) [71] , which is an antiplatelet agent and inhibitor of phosphodiesterase (PDE) [72 , 73 ] has been shown to possess a broadspectrum antiviral activity and binds to the active site of M pro . It has also been shown to reduce inflammation, mucosal thickening, and injury of the lung, heart, liver, and kidney [71] .

Unlike M pro , PL pro can not only cleave the viral polypeptide but also can suppress host innate immune responses via the reversal of posttranslational modification of proteins by ubiquitin (Ub) and interferonstimulated gene product 15 (ISG15) [ 74 , 75 ] . Hence its inhibition is expected to stall replication and translation of the virus and may help in keeping the host's immune intact. Recently, Naphthalene based inhibitors are shown to inhibit PL pro protease of the SARS-CoV-2 [76] . Virtual screening studies have identified several antivirals (Ribavirin, Valganciclovir, etc.), antibacterial (Chloramphenicol, Cefamandole, etc.), antitussive (Levodropropizine), and muscle relaxant drugs (Chlorphenesin carbamate) for the inhibition of PL pro activities [77] . However, the [82] . In this structure, RemTP was converted to RemMP for incorporation in the RNA strand and two dissociated phosphate groups were stabilized by the Mg + 2 ions. The bindings of nsp7 and nsp8 to the RdRp are also shown. measurements of in vivo activities and toxicities of these drugs are yet to be carried out.

The viral RNA genome binds to the active site of the nsp12 (RdRp) for the synthesis of new strands, which then produces daughter viral genomes via RNA replication. Hence, the RdRp is mainly responsible for the proliferation of the virus inside the host cells [78] [79] [80] [81] . Therefore, blocking the binding of RNA to RdRp can prohibit the replication of the virus. Recent cryo-EM studies have demonstrated that the first turn of the RNA binds to the RdRp clamped between its Finger and Thumb subdomains [78] [79] [80] [81] . The active site of RdRp was found to be located on the Palm subdomain formed by five conserved motifs, such as A, B, C, D, and E. Motif C binds to the RNA 3 ′ -end and contains the catalytically important residues Asp760 and Asp761, which are required for the synthesis of RNA nucleotides [78] [79] [80] [81] . The metal ions found in most of the viral RdRps are coordinated by these residues. Similarly, the Finger subdomain contains motifs F and G that help in the proper positioning of the RNA template ( Fig. 4 ) . Interestingly, it was observed that during the exit of the RNA from the RdRp cleft, it forms a second helical turn that protrudes from the RdRp surface [78] . These results indicate that a double-stranded RNA is formed during the replication. However, it is not known whether a double-stranded RNA would still be formed in infected cells. If yes, how can it be separated during the transcription of viral genes, so that a single-stranded product mRNA can be translated? Although mechanisms of transcription of single-stranded mRNAs in the infected cells are not known, several structural studies have emphasized that a double-stranded RNA would occur during the replication. Hence, designs of nucleotide inhibitors are of paramount importance to inhibit the replication of the virus.

It should be mentioned that the inhibition of the replication of the virus can be achieved in two ways. According to the first mechanism, a non-canonical RNA or DNA nucleotide can be inserted into the RNAstrand, which cannot be recognized by RdRp during the replication. As a result, the chain-elongation reaction of the viral RNA will be stalled. According to the second mechanism, an inhibitor can bind to RdRp to block the entry of the viral RNA into the active site of RdRp for processing. For example, recently, Remdesivir, [82] [83] [84] [85] , a non-canonical nucleotide, has been shown to inhibit the replication of the SARS-CoV-2 via the first mechanism. As it contains a membrane-permeable backbone, it can easily reach the cytoplasm where it would be converted to Remdesivir monophosphate (RemMP) and finally to Remdesivir triphosphate (RemTP) ( Fig. 5 ) before binding to the RNA [ 83 , 84 ] . RemTP is believed to be the drug metabolite that inhibits the replication of the viral RNA [82] . A recent Cryo-EM study has shown that the prodrug of Remdesivir i.e. RemMP gets covalently incorporated into the primer strand of the RNA virus at the first replicated base pair and terminates RNA chain elongation as illustrated in Fig. 4 [82] . To explore the second mechanism, recent docking and MD-studies have shown that while Remdesivir can bind to the active site of RdRp and remains stable during MD-simulations, RemMP gets rotated away from the binding site during simulations [85] . For this reason, the relative binding free energy of RemMP is found to be positive and less stable than that of Remdesivir [86] . In another MD-simulation study [87] , RemTP was shown to bind to the active site strongly. It was presumed that RemTP would initially bind to the RdRp active site as a preinsertion complex and eventually would be transported into the RNA strand [87] . However, to be covalently bound to the RNA, RemTP needs to be converted to RemMP ( Fig. 5 ) for proper sealing of the RNA strand. Hence, the molecular mechanisms of the inhibition of replication of the viral RNA by Remdesivir are not yet fully known.

Like Remdesivir, Favipiravir (T-705, Avigan), which is a pyrimidinebased antiviral drug used for the treatment of influenza A, B, and C viruses [ 88 , 89 ] , was proposed to bind to the RdRp in its drug metabolite triphosphate form i.e. Favipiravir-ribofuranosyl-5 ′ -triphosphate (Favipiravir-TP) ( Fig. 5 ) . It was speculated that either Favipiravir-TP would be incorporated into the viral RNA strand to stop the RNA-chain elongation reaction or bind to the conserved residues of the RdRp, thereby blocking the entry and exit of the viral RNA [ 88 , 89 ] . Favipiravir was also proposed to induce severe mutations above the catastrophe error limit [90] [91] [92] .

Triazavirin, which is a guanine nucleotide analog and was originally found to be helpful against influenza (A and B) and H5N1 viruses, has been proposed to be beneficial for the inhibition of SARS-CoV-2 replication presumably by promoting the RNA-chain termination reaction [93] . However, a modeling study by considering its prodrug form has shown that it's binding to RdRp is weaker compared to Remdesivir [94] . Similarly, Ribavirin which is a guanosine analog and was used for the treatment of respiratory syncytial virus (RSV) infections [95] , hepatitis C [96] , and a few viral hemorrhagic fevers [97] , has been shown to interfere with the replication of RNA by inhibiting the activities of the RdRp protein of the SARS-CoV-2. Moreover, Ribavirin has been shown to inhibit the formation of natural guanosine by directly inhibiting inosine monophosphate dehydrogenase, which is vital for the production of guanosine [98] . Like Favipiravir, it is also proposed to be mutagenic. For these reasons, Ribavirin is in clinical trial against COVID-19 [99] . Interestingly, the binding of Ribavirin to the RdRp protein is found to be less favorable compared to Remdesivir [94] . Similarly, Galidesivir, which is an adenosine nucleoside analog and blocks RNA polymerase of the Ebola virus [100] , Zika virus [101] , and Yellow Fever virus [102] , has been proposed to block the RdRp of SARS-CoV-2 [103] .

Recently, EIDD-1931 and EIDD-2801 have been proposed to be useful for the treatment of COVID-19 [ 104 , 105 ] . The EIDD-2801 is the isopropyl ester prodrug of EIDD-1931 (N4-hydroxycytidine), which has been shown to inhibit the replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells [ 104 , 105 ] . Similarly, EIDD-1931, which is a ribonucleoside analog and induces mutations in RNA virions, has also been shown to be beneficial for the treatment of COVID-19 [104] . It was also demonstrated to inhibit coronaviruses that are resistant to remdesivir [104] . Interestingly, EIDD-1931 was found to exist in two tautomeric forms [104] . In one form (EIDD-1931-t1), it mimics cytidine, with a single bond between the carbon and N-OH group, while in the other form (EIDD-1931-t2), it mimics uridine due to an oxime group with a double bond between the carbon and N-OH group ( Fig 5 ) . When the virus grows in the presence of EIDD-1931, its RNA-dependent RNA polymerase reads EIDD-1931-t1 as uridine (instead of cytidine) and inserts adenosine (instead of guanosine) opposite it ( Fig 5 ) [ 104 , 105 ] . Interestingly, in a nonradioactive primer extension assay [105] , it was found that the EIDD-1931-triphosphate can be incorporated as a C-analog at the + 2 position, G-analog at the + 3 position, and U-analog at the + 4 position when no competing natural GTP or UTP is present [104] . Recently, by using density functional studies, it was shown that EIDD-1931 would make the most stable base-pair with G, while EIDD-2801 would make almost isoenergetic base pairs with U, A, and G [106] . These base-pairs were proposed to induce mutations in the RNA. Interestingly, Remdesivir, Galidesivir, Favipiravir, and Ribavirin were also found to form mutagenic base pairs in the RNA by adopting different tautomeric conformations [106] . For example, the insertions of G and U were found to be preferred against the amino tautomer of Remdesivir and Galidesivir, while the insertion of C was found to be favored against their imino tautomers. Similarly, the incorporations of G, C, A, and U were found to be possible opposite the keto tautomer of Favipiravir, while the insertion of C opposite the keto tautomer of Ribavirin was found to be favorable [106] . It should be noted that although Favipiravir and Ribavirin were known to exhibit antiviral properties through base-pair mutations, for the first time, Remdesivir and Galidesivir were proposed to follow the same mechanism to inhibit the replication of the viral genome [106] .

It was recently shown that different synthetic DNA nucleotides can bind to RdRp more firmly than those of known nucleotide antiviral drugs [86] . The two and three nucleotide sequences of these synthetic nucleotides were found to bind to RdRp even more strongly. In addition to these, several other nucleotide inhibitors, such as Sofosbuvir, Alovudine, Tenofovir, Alafenamide, AZT, Abacavir, Lamivudine, and Emtricitabine have also been proposed to inhibit the replication of viral RNA [107] . Further, as the RNA binding site of RdRp contains several conserved charged amino acids and positively charged metal ions, it is possible that ionic peptides can bind to RdRp more tightly compared to small molecule inhibitors [108] . It should be mentioned that peptide inhibitors have the advantage of better tissue penetration, cost-effectiveness, better specificity, and lower toxicity (because of safer metabolite) [109] . However, due to their structural flexibility, variable solubility, low bioavailability, and less stability (can easily be degraded by proteolytic enzymes), the number of peptide inhibitors currently used as drugs against various diseases are less compared to the organic ligands. However, chemical modifications in the peptides, such as Cterminal amidation, N terminal acetylation, and the use of non-natural amino acids at different sites can enhance their drugability by overcoming these limitations [109] .

It was speculated that binding of nsp7 and nsp8 to RdRp is required for the correct functioning of the polymerase [82] . Although these nonstructural proteins bind to RdRp remotely from its active site, their binding helps the double-stranded RNA to enter into the active site of RdRp [82] . Hence, the blocking of the nsp7-RdRp and nsp8-RdRp interfaces may prevent the RNA from entering the active site of RdRp. Recently, by using virtual screening studies, several inhibitors that may bind to RdRp-nsp7 and RdRp-nsp8 interfaces have been proposed [110] . However, the in vivo use of these ligands has not yet been studied.

Recently, the structure of RdRp in complex with an RNA, two nsp13 helicases, two nsp8, and one nsp7 protein has been resolved by a cryo-EM study [111] ( Fig. 6 ) . In this complex, the N-terminal domain of each nsp13 was interacting with the N-terminal extension of each nsp8. One nsp13 was also interacting with the Thumb domain of RdRp ( Fig. 6 ) . Similarly, the nucleic acid-binding ATPase domain of each nsp13 was located directly in front of the RdRp, thereby constraining the function of nsp13 [111] . Thus, it was proposed that nsp13 may generate either backtracked replication or transcription complexes for proofreading or template-switching during sub-genomic RNA transcription, or both. Interestingly an adenosine diphosphate (ADP)-Mg 2 + binding to the NiRAN domain of RdRp was observed in this study ( Fig. 6 ) . Although the roles of this pocket and ADP are not exactly known, it is speculated that it may help in the transfer of adenosine monophosphate (AMP) to the active site of RdRp, which may help in the synthesis of the viral RNA. Hence, this pocket may aid in future antiviral drug design [111] .

The nsp1 protein suppresses host gene expression and induces a nearcomplete shutdown of host protein translation by binding to the ribosomal subunit. This binding also leads to the endonucleolytic cleavage and subsequent degradation of host mRNAs. As a result, all of the cellular antiviral defense mechanisms are inhibited. Hence, the inhibition of nsp1 would be beneficial to develop host cell immune response and reduce viral cell replication [112] . Structural studies have found that nsp1 binds to the 40S ribosomal subunit, which ultimately prohibits the translation of mRNA. It is further found that the C-terminus of nsp1 binds and obstructs the entry channel of mRNA. Although no therapeutic candidates targeting the mRNA active site of nsp1 have been studied so far, it is expected that nsp1 would emerge as a new antiviral drug target in near future.

The nsp9 is believed to mediate both viral replication and virulence. It binds to RNA via a unique fold characteristic of -coronaviruses that contains an -helical GxxxG interaction motif (x stands for any other residue) [113] . Recently, the crystal structures of nsp9 in the apo conformation and a peptide bound form have been solved [113] . The peptidebinding site is found to be very close to the dimer interface and this unique fold. It was thus proposed that the disruption of the dimer interface of nsp9 may affect the binding of RNA to this fold and hence may inhibit its function [ 113 , 114 ] . Therefore, it is necessary to target this fold with novel therapeutic candidates to block the binding of RNA to nsp9.

The coronavirus M-protein is the most abundant viral protein that plays a key role in virion assembly [115] . One of its functions is to mediate the incorporation of the S-proteins into the viral envelope. The M-protein and S-protein complex formation was found to be sensitive to changes in the transmembrane domains [116] . Amino acid deletions in the amphipathic domain of the M-protein were found to affect the M-S interactions. However, changes in the amino-terminal and extreme carboxy-terminal domains of the M-protein were demonstrated to be fatal to the ability of the M-protein to engage in the formation of the virus particle [116] . Hence, the structural requirements of the M protein for virus particle assembly differ from the requirements for the formation of M-S complex [116] . In addition to M-S interactions, M-M and Mnucleocapsid (N) protein interactions are also facilitated by M-protein during viral assembly [116] . Among these interactions, the M-M interactions constitute the overall scaffold for the viral envelope [116] . In silico analyses of the M protein of SARS-CoV-2 have identified three important transmembrane domains for its function. The N-and C-terminals of the M-protein were found to be exposed outside and inside the virus particle, respectively [117] . Hence, it is believed that drugs that can disrupt the M-S and M-N protein interactions can help in the reduction of the assembly and packaging of the SARS-CoV-2.

The E-protein is the smallest (76-109 amino acids) but very important viral protein that plays a prominent role in virus assembly, budding, envelop formation, membrane permeability, and pathogenesis [118] . In the case of several viruses, the E-protein was found to carry a fusion peptide at the top and transmembrane regions at the bottom. In Fig. 6 . The cryo-EM structure of the RdRp-RNA-nsp7-nsp8-nsp13 complex (PDB ID 6XEZ) [111] . The bindings of nsp13 and ADP with the Thumb and NiRAN domains of RdRp respectively are also shown. . between, it has three distinct domains connected by flexible hinges to mediate conformational changes during the viral life cycle [118] . The primary and secondary structures of -coronaviruses have revealed that the E-protein contains three major regions, such as (1) a short and hydrophilic amino terminus (7-12 amino acids), (2) a large hydrophobic transmembrane domain (TMD) (~25 amino acids), and (3) a long and hydrophilic carboxyl terminus [118] . Recently, the SARS-CoV E-protein was structurally characterized. It was found to contain a PDZ-binding motif (PBM), located in the last four amino acids of the C terminus [ 119 , 120 ] . The PDZ domain is a protein-protein interaction domain that can bind to the target proteins, such as the cellular adapter proteins involved in the viral infection [ 119 , 120 ] . Some interaction partners capable of binding to the PDZ domain of SARS-CoV E have been identified, which may have a direct role in viral pathogenesis [121] . It is also believed that the PDZ domains in different coronaviruses bind to the host's syntenin protein resulting in overexpression of inflammatory cytokines and hence induce the cytokine storm. Additionally, the E-protein of coronaviruses can be embedded into the ERGIC/Golgi membranes, thereby inducing Ca + 2 transportation and overproduction of interleukin 1 .

Unfortunately, there is no crystal or cryo-EM structure of the SARS-CoV-2 E protein. However, sequence comparison of different coronaviruses has shown that the E-protein of SARS-CoV-2 is identical to that of Bat and Pangolin coronaviruses with a minor difference in the sequence [122] . Experimental data revealed that the E protein of SARS-CoV-2 is a single-spanning membrane protein with the N-terminus being translocated across the membrane, while the C-terminus is exposed to the cytoplasmic side (Nt lum /Ct cyt ) [122] . These studies suggest that the inhibition of the N-terminal region can help in blocking the viral fusion, replication, and transcription of SARS-CoV-2. In addition to this, it was also revealed that during fusion, the transmembrane region of the viral E-protein can make a pore in host cell membranes, which may alter the transmembrane potential of host cells and serve as a marker of viral infection [123] . This pore can act as an ion channel, which can be inhibited to suppress viral activities. For example, the Hexamethylene amiloride (HMA) drug was used to inhibit the ion channel activities and viral replication of some synthetic coronavirus E proteins, [123] . Similarly, modeling studies have proposed some phytochemicals [124] and other molecules [125] to inhibit the ion channel activities of the E-protein. However, no specific E-protein inhibitors of SARS-CoV-2 have been identified to date.

The primary functions of the N-protein are to bind to the viral RNA genome and pack it into a long helical nucleocapsid structure or ribonucleoprotein (RNP) complex [126] . This is essential to generate a highly ordered viral RNA conformation suitable for replication and transcription. The common domain architecture of coronavirus N-protein consists of three distinct but highly conserved parts, such as (1) an Nterminal RNA-binding domain (NTD), (2) a C-terminal dimerization domain (CTD), and (3) an intrinsically disordered central Ser/Arg (SR)-rich linker [ 127 , 128 ] . Previous studies have revealed that the NTD is responsible for RNA binding, CTD for oligomerization, and (SR)-rich linker for primary phosphorylation, respectively [ 129 , 130 ] . Recently, a crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 was solved [131] ( Fig. 7 ) . The superposition of this structure onto the NTD of HCoV-OC43 N-protein [131] has identified the adenine monophosphate (AMP) binding site ( Fig. 7 ) . It was further found that its N-terminal tail residues, such as Asn48, Asn49, Thr50, and Ala51 are quite flexible and extended outward, opening up the binding pocket to include the viral RNA. The Arg89 was proposed to help in the recognition of the AMP [131] . Although the full-length structure of the N-protein of SARS-CoV-2 has not been observed yet, this study [131] has identified a putative nucleotide-binding site, which can be inhibited by nucleotide drugs to suppress the activities of the N-protein.

Although a rapid immune response is necessary against viral infection, dysregulated and excessive immune responses may cause damage to the human body. It was found that at the preliminary stage of COVID-19, patients show mild symptoms like fever, cough, muscle soreness, etc. However, critical patients show a sudden ARDS and multiple organ failures mainly due to the cytokine storm [132] . For example, i n vitro cell experiments have shown that during the early stage of COVID-19, the release of cytokines and chemokines occur very late in respiratory epithelial cells, dendritic cells (DCs), and macrophages [132] [133] [134] . However, later, the cells secrete high levels of proinflammatory cytokines (interleukin (IL)-1 , IL-6, tumor necrosis factor (TNF)), chemokines, and low levels of the protective antiviral factor interferons (IFNs) [133] . Hence, the suppression of the cytokine storm is vital to save human lives [134] . [131] . The superposed structure of SARS-CoV-2 N-protein (monomer 1) onto the HCoV-OC43 N-protein bound to adenosine monophosphate (AMP) (PDB ID 4LI4) [131] are shown to indicate the nucleotide-binding site of the N-protein.

Corticosteroids are a class of steroid hormones that have antiinflammatory functions [135] . For this reason, they are mainly used in critically ill patients suffering from an inflammatory cytokine storm [135] . Dexamethasone is a corticosteroid and is normally used to treat inflammation, asthma, bronchitis, endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, etc. Recently, it is shown to be very useful for critical COVID-19 patients suffering from ARDS. Although corticosteroids bind to the glucocorticoid receptor, which mediates changes in gene expression that may lead to multiple downstream effects, the exact role of Dexamethasone in suppressing SARS-CoV-2 is not known. Similarly, the use of Methylprednisolone and Hydrocortisone has also been found to be useful for the treatment of COVID-19 [64] .

It was shown that inhibition of IL-1 can suppress the cytokine storm. Therefore, Anakinra, an antagonist of IL-1 , was proposed for the treatment of the cytokine storm caused by infection [136] . Similarly, the use of Tocilizumab and Etoposide was shown to be beneficial for patients with bilateral lung lesions related to elevated IL-6 levels [ 137 , 138 ] . Chloroquine was also suggested to inhibit the production and release of TNF and IL-6 and hence may reduce cytokine storm [139] . Ulinastatin, a serine protease inhibitor has been shown to suppress the activities of proinflammatory cytokines such as TNF-, IL-6, and IFN-, and increase the level of anti-inflammatory factors like IL-10. Therefore, it was proposed to be vital for the suppression of cytokine storm [140] . Similarly, the use of interferon-was recently shown to be beneficial for COVID-19 patients [141] .

Ruxolitinib, which is a Janus kinase (JAK1 and JAK2) inhibitor and a therapeutic of bone marrow cancer, has been proposed to be useful for the treatment of COVID-19 [142] . It should be mentioned that Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway [142] . For this reason, Ruxolitinib was proposed to be beneficial for COVID-19 patients. Recently, the efficacy and safety of Ruxolitinib for COVID-19 was conducted in a randomized, multicentre, placebocontrolled, single-blind phase II trial in patients hospitalized with severe COVID-19 [143] . It was found that patients treated with Ruxolitinib rapidly recovered from COVID-19 [143] . Similarly, Baricitinib, which is another JAK1/JAK2 inhibitor, and is in use for the treatment of rheumatoid arthritis, has also been proposed to be useful for the treatment of COVID-19 by controlling cytokine storm [144] . These drugs may also block the host cell proteins involved in viral reproduction and reduce the ability of infected cells to produce more viruses. Similarly, Bemcentinib, which is an inhibitor of AXL kinase has been proposed to be beneficial for the treatment of COVID-19 [145] . Thus, the inhibition of AXL kinase activity is believed to help in the blocking of viral entry and enhancing the protective antiviral type I interferon response.

Although several antiviral drugs and immune boosters as listed in Table 1 are found to be useful against COVID-19, the concrete evidence about their in vivo activities (safety, toxicity, side effects, mortality, etc.) in human cells are not known with certainty. This is because the previous studies in which the usefulness of these drugs was claimed, suffer from severe limitations, such as (1) tested in non-human samples, (2) method of testing was not robust, (3) inadequate data were analyzed, etc. For example, recently, the ReFRAME (repurposing, focused rescue, and accelerated med chem) drug library was screened in a cell-based assay (non-human samples) to identify existing drugs that may show antiviral property against SARS-CoV-2 [146] . This study has identified about 100 drugs that may inhibit SARS-CoV-2 replication in mammalian cells, including Remdesivir [146] . However, in a solidarity test on four repurposed drugs, such as Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon − 1a against COVID-19 undertaken by WHO and its partners, it is found that these drugs have a little or no effect on the overall mortality, initiation of ventilation and duration of hospital stay in hospitalized patients. As in these randomized trials, about 11,330 patients in 405 hospitals, in almost 30 countries were participated [ 147 , 148 ] , these results are reliable. This type of test is now being extended to evaluate the efficacies of other drugs and is expected to help to identify potent drugs against COVID-19. Similarly, in another clinical study, the use of Arbidol was found to be ineffective to alleviate symptoms of COVID-19, conversion of RT-PCR positive report to negative, duration of hospital stay, and adverse events [149] .

Vitamin C (ascorbic acid) is an antioxidant that plays an important role in neutralizing free radicals and assists to prevent cellular damage [150] [151] [152] [153] . Further, it possesses antiviral properties. Due to these reasons, it was found to be beneficial against viral diseases, in particular against influenza viruses [150] . Further, it was found to suppress the development and maturation of T lymphocytes and natural killer cells to enhance the immune response against viral cells [150] . It can also help in the modulation of cytokines and improve the function of phagocytes, boost the production of interferon, and reduce inflammation [151] . Recently, the consumption of Vitamin C was found to suppress respiratory tract infections in COVID-19 patients [ 152 , 154 ] . Flavonoids are also found to possess antiviral activities [155] . Among different flavonoids, Quercetin, which is mainly found in vegetables, leaves, seeds, and grains, where it is conjugated with residual sugars to form Quercetin glycosides, has been proposed to be beneficial for the treatment of COVID-19 [156] . Like Vitamin C, Quercetin acts as an antioxidant, free radical scavenger [157] , and anti-inflammatory. For these reasons, it was found to inhibit the aggregation of platelet and lipid peroxidase [ 157 , 158 ] . In vitro and in vivo studies have demonstrated that Quercetin can inhibit virus entry, replication, and transcription in host cells [158] .

Vitamin D is known to enhance antimicrobial activity against several pathogens including respiratory (syncytial virus, influenza, and coronaviruses) and non-respiratory viruses (HIV 1, Hepatitis C, and Dengue viruses) [159] [160] [161] [162] [163] [164] [165] . The antiviral property of Vitamin D is associated with its ability to regulate antimicrobial peptides and induce antiviral cytokines to interfere in the viral replication and translation [159] [160] [161] [162] [163] [164] [165] . Vitamin D was also found to target the early stage of the viral cycle by downregulating the expression of host cell receptors for viral attachment [159] [160] [161] [162] [163] [164] [165] . As the binding of SARS-CoV-2 to the ACE2 protein is one of the main reasons for viral entry into host cells, patients suffering from hypertension, diabetes mellitus, coronary heart diseases, and cerebrovascular disease, are at high risk of COVID-19 due to the higher expression of ACE2 protein in these conditions [162] [163] [164] . . However, recent in vitro and in vivo studies have demonstrated that Vitamin D can down-regulate the expression of ACE2 and suppress RAS proteins and therefore may provide an immune response against COVID-19 [162] [163] [164] . Its uptake has also been shown to reduce the risk of acute viral respiratory tract infections and pneumonia, presumably due to the inhibition of the replication of the virus or induction of anti-inflammatory and immune-modulatory activities [159] [160] [161] [162] [163] [164] [165] .

Zn ion (Zn + 2 ) is considered to possess anti-oxidant and antiinflammation properties and helps in the physiological functioning of immune systems by acting as a signaling molecule. Its deficiency has been implicated in phagocytosis, target cell killing, and cytokine pro-duction. Hence, it is believed that Zn plays an important role in inducing antiviral activities in cells like vitamins C and D [166] . Its use in COVID-19 patients has been shown to be beneficial.

In this review article, a detailed overview of the current status of the research on the therapeutic inventions for COVID-19 has been discussed. Although no SARS-COV-2 specific drug has been invented to date, repurposing of old drugs has shown great potential in treating COVID-19. It is found that the detailed understanding of structures and functions of SARS-CoV-2 in inducing COVID-19 has immense importance in discovering new therapeutics. As the research on COVID-19 is evolving more and more, new interesting discoveries are emerging. These findings have helped to recognize new drug targets. For example, in addition to RdRp (nsp12), nsp1 and nsp9 have emerged as new drug targets. Similarly, interfaces of non-structural proteins like the interfaces of RdRp-nsp7, RdRp-nsp8, and RdRp-nsp13 have also emerged as new drug targets. Further, in addition to the ACE2 receptor binding site of S-protein, priming site of S2 subunit, interfaces of HR1 and HR2 domains, etc. can be targeted to design new drugs . Various other structural proteins, such as E, M, and N, and their interaction sites are also identified as new drug targets to inhibit viral assembly, budding, and release. Similarly, the substrate-binding sites of different proteases are attractive drug targets. As several non-structural proteins are not yet fully characterized, it is expected that many more new drug targets will be invented in near future. Due to the involvements of multiple drug targets and their close associations, combination of multiple drugs targeting these sites simultaneously may yield better results against COVID-19. However, these drugs should be very specific to their targets, so that they are not binding to off-targets to induce side effects.

There are no conflicts of interest to declare.

Early transmission dynamics in Wuhan, China, of novel coronavirus infected pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan China

A major outbreak of severe acute respiratory syndrome in Hong Kong

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

Epidemiology of coronavirus respiratory infections

Coronavirus infections-more than just the common cold

Multiorgan and renal tropism of SARS-CoV-2

Cytokine storm and sepsis disease pathogenesis

Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells

The pathogenesis and treatment of the cytokine storm in COVID-19

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system

ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19

Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases

-2019)-and-the-virus-that-causes-it#:~:text = The%20International%20Committee%20on%20Taxonomy

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B beta coronaviruses

How does SARS-CoV-2 cause COVID-19

Structural basis of receptor recognition by SARS-CoV-2

What Do We Know About the Novel Corona Virus's 29 Proteins

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response

A perspective on multi-target drug discovery and design for complex diseases

Viral and cellular mRNA translation in coronavirus-infected cells

A novel activation mechanism of avian influenza virus H9N2 by furin

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is locked by a clinically proven protease inhibitor

Distinct conformational states of SARS-CoV-2 spike protein

COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS

The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons

Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with hepatitis C virus genotype 1 or 3 infections

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Cell entry mechanisms of SARS-CoV-2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries

Clinical trials on drug repurposing for COVID-19 treatment

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine for the Prevention of Covid-19-searching for evidence

Nafamostat mesylate blocks activation of SARS-CoV-2: a new treatment option for COVID-19

Therapeutic uses of furin and its inhibitors: a patent review

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity

The coronavirus replicase

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction

Crystal structure of SARS-CoV-2 main protease provides a basis for the design of improved -ketoamide inhibitors

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

HIV protease inhibitors: a review of molecular selectivity and toxicity

Structure, and mechanism of the complex between cytochrome P4503A4 and ritonavir

Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019

Does lopinavir really inhibit SARS-CoV-2?

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation-based drug-repurposing

Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection

Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmaco enhancer

Structural similarity of SARS-CoV2 M pro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics

Ongoing clinical trials for the management of the COVID-19 pandemic

Peptide-like and small-molecule inhibitors against Covid-19

Screening of FDA approved drugs against SARS-CoV-2 main protease: coronavirus disease

SARS-CoV-2 M pro inhibitors: identification of anti-SARS-CoV-2 M pro compounds from FDA approved drugs

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M pro

Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19

Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2

Covalent Versus Non-covalent enzyme inhibition: which route should we take? a justification of the good and bad from molecular modelling perspective

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Anti-platelet therapy: phosphodiesterase inhibitors

Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis

Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme

Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Structural basis for RNA replication by the SARS-CoV-2 polymerase

Structure of replicating SARS-CoV-2 polymerase

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

RNA dependent RNA polymerases: insights from structure, function and evolution

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19

A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir

Remdesivir is a direct-acting antiviral that inhibits RNA dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Artificially expanded genetic information systems (AEGIS) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2

Structural basis of the potential binding mechanism of Remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase

T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 Viruses, Vitro

Favipiravir and zanamivir cleared infection with influenza B in a severely immune compromised child

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Experimental treatment with favipiravir for COVID-19: an open-label control study

Favipiravir: a possible pharmaceutical treatment for COVID-19

Efficacy and safety of triazavirin therapy for coronavirus disease 2019: a pilot randomized controlled trial

Identification of potent drugs and antiviral agents for the treatment of the SARS-CoV-2 infection

Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immune compromised patients

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug

Mechanisms of action of ribavirin against distinct viruses

Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19

BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques

BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Analysis of the potential for N4-hydroxycytidine to inhibit mitochondrial replication and function

Role of different tautomers on the base-pairing abilities of some of the vital antiviral drugs used against COVID-19Phys

Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19

Inhibition of the RNA-dependent RNA polymerase of SARS-CoV-2 by peptide inhibitors

Peptides as drug candidates: limitations and recent development perspectives

SARS-CoV-2 and SARS-CoV: virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)

Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Crystal structure of the SARS-CoV-2 non-structural protein 9

Severe acute respiratory syndrome coronavirus nsp9 dimerization is essential for efficient viral growth

Coronavirus particle assembly: primary structure requirements of the membrane protein

Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein

Sars-CoV-2 Envelope and membrane proteins: structural differences linked to virus characteristics?

Structures and functions of the envelope glycoprotein in flavivirus infections

Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses

The role of flexibility and conformational selection in the binding promiscuity of PDZ domains

Coronavirus envelope protein: current knowledge, Virology

SARS-CoV-2 envelope protein topology in eukaryotic membranes

Structure and inhibition of the SARS coronavirus envelope protein ion channel

In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs

The SARS coronavirus nucleocapsid protein-forms and functions

Multiple nucleic acid binding sites and intrinsic disorder of severe acute respiratory syndrome coronavirus nucleocapsid protein: implications for ribonucleocapsid protein packaging

Transient oligomerization of the SARS-CoV N protein-Implication for virus ribonucleoprotein packaging

Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein

Phosphorylation of the porcine reproductive and respiratory syndrome virus nucleocapsid protein

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Can steroids reverse the severe COVID-19 induced "cytokine storm?

Corticosteroids in the treatment of acute asthma

Anti-inflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1

Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19

Potential treatments for COVID-19 related cytokine stormbeyond corticosteroids

Chloroquine inhibits proinflammatory cytokine release into human whole blood

Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study

Type 1 interferons as a potential treatment against COVID-19

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact

736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

WHO solidarity trial consortium, repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results, New Engl

Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and metaanalysis

Influence of vitamin C on lymphocytes: an overview

Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-alpha/beta at the initial stage of influenza A virus (H3N2) infection

Quercetin and Vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19)

Vitamin C-an Adjunctive Therapy For Respiratory infection, Sepsis and COVID-19

Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases

Antioxidative and prooxidative effects of quercetin on A549 cells

Quercetin inhibits rhinovirus replication in vitro and in vivo

Vitamin D supplementation: a potential approach for coronavirus/COVID-19 therapeutics? Front. Immunol. 2020

Modulation of the immune response to respiratory viruses by vitamin D

LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults

Vitamin D deficiency and co-morbidities in COVID-19 patients -A fatal relationship? Nfs

Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure

Role of vitamin D in preventing of COVID-19 infection, progression and severity

Vitamin D can prevent COVID-19 infection-induced multiple organ damage

Zinc and COVID-19: basis of current clinical trials

NRJ is thankful to the Science and Engineering Research Board (NewDelhi, India) for financial support.